Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jan 29:149:e40.
doi: 10.1017/S0950268821000236.

Thrombocytopenia as a prognostic marker in COVID-19 patients: diagnostic test accuracy meta-analysis

Affiliations
Meta-Analysis

Thrombocytopenia as a prognostic marker in COVID-19 patients: diagnostic test accuracy meta-analysis

Raymond Pranata et al. Epidemiol Infect. .

Abstract

This systematic review and meta-analysis aimed to evaluate thrombocytopenia as a prognostic biomarker in patients with coronavirus disease 2019 (COVID-19). We performed a systematic literature search using PubMed, Embase and EuropePMC. The main outcome was composite poor outcome, a composite of mortality, severity, need for intensive care unit care and invasive mechanical ventilation. There were 8963 patients from 23 studies. Thrombocytopenia occurred in 18% of the patients. Male gender (P = 0.037) significantly reduce the incidence. Thrombocytopenia was associated with composite poor outcome (RR 1.90 (1.43-2.52), P < 0.001; I2: 92.3%). Subgroup analysis showed that thrombocytopenia was associated with mortality (RR 2.34 (1.23-4.45), P < 0.001; I2: 96.8%) and severity (RR 1.61 (1.33-1.96), P < 0.001; I2: 62.4%). Subgroup analysis for cut-off <100 × 109/l showed RR of 1.93 (1.37-2.72), P < 0.001; I2: 83.2%). Thrombocytopenia had a sensitivity of 0.26 (0.18-0.36), specificity of 0.89 (0.84-0.92), positive likelihood ratio of 2.3 (1.6-3.2), negative likelihood ratio of 0.83 (0.75-0.93), diagnostic odds ratio of 3 (2, 4) and area under curve of 0.70 (0.66-0.74) for composite poor outcome. Meta-regression analysis showed that the association between thrombocytopenia and poor outcome did not vary significantly with age, male, lymphocyte, d-dimer, hypertension, diabetes and CKD. Fagan's nomogram showed that the posterior probability of poor outcome was 50% in patients with thrombocytopenia, and 26% in those without thrombocytopenia. The Deek's funnel plot was relatively symmetrical and the quantitative asymmetry test was non-significant (P = 0.14). This study indicates that thrombocytopenia was associated with poor outcome in patients with COVID-19.PROSPERO ID: CRD42020213974.

Keywords: Coronavirus; mortality; platelet; severe; thrombocyte.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Fig. 1.
Fig. 1.
PRISMA flowchart.
Fig. 2.
Fig. 2.
Forest-plot for thrombocytopenia and composite poor outcome (a) and pooled sensitivity and specificity (b).
Fig. 3.
Fig. 3.
Fagan's nomogram.
Fig. 4.
Fig. 4.
Deek's funnel plot and asymmetry test. The vertical axis displays the inverse of the square root of the effective sample size (1/root(ESS)).
Fig. 5.
Fig. 5.
Summary receiver operating characteristic (SROC) with prediction and confidence contours.
Fig. 6.
Fig. 6.
Univariable meta-regression and subgroup analyses. Vertical lines represent pooled sensitivity and specificity, respectively.

References

    1. Huang I et al. (2020) C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Therapeutic Advances in Respiratory Disease 14, 175346662093717. - PMC - PubMed
    1. Huang I and Pranata R (2020) Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. Journal of Intensive Care 8, 36. - PMC - PubMed
    1. Henrina J, Lim MA and Pranata R (2020) COVID-19 and misinformation: how an infodemic fueled the prominence of vitamin D. British Journal of Nutrition 125, 359–360. doi: 10.1017/S0007114520002950. - DOI - PMC - PubMed
    1. Wells G et al. (2009) The Newcastle–Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp).
    1. Higgins JP and Green S (2011) 9.6.4 Meta-regression. Cochrane Handbook for Systematic Reviews of Interventions. UK: Cochrane.

MeSH terms